Free-To-Play Fantasy MMORPG Mabinogi Celebrates Its 14th Anniversary On March 27!
24.3.2022 22:00:00 EET | Business Wire | Press release
Today, leading game publisher Nexon announced its venerable free-to-play fantasy MMORPG Mabinogi will be celebrating its 14th anniversary on March 27. Players will be able to engage in celebratory bonuses and activities for the game’s anniversary through April 14. As part of continuing quality of life improvements, Mabinogi will also be merging servers on April 14, so that global players can continue to embark on mystical adventures together.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005803/en/
Mabinogi (Graphic: Business Wire)
The 14th anniversary celebration will include an abundance of updates from equipment repair cost reduction to 20% of the original price to Crom Bás dungeon polishing such as increased drop rate and overall dungeon length reduction. Additionally, the celebration brings a range of prizes, new missions and quests, starting on March 17, including:
- 14th Anniversary Night Bazaar - Meet Dero the Eventsman near Festia’s Main Gate and register your main character to participate in this guide quest, receive prizes, and play mini-games. Plus, all characters will be able to receive a 14th Anniversary Check design when issuing a check from the Tir Chonaill bank.
-
14th Anniversary Quests
-
Bazaar Experience - This achievement quest rewards players with a special Festival Souvenir Hebona Robe sewing pattern with the opportunity to win a Festival Commemorative Luxury Equipment Bag Box, 20,000 EXP, and 25 instant prize tickets after completing all objectives.
- Daily Quests: Finding Fruitful Fulfillment - Every day brings a different task for players to compete around the Night Bazaar for rewards. Players will be able to receive Cotton Candy from the Dessert Merchant, play in a variety of mini-games, and embark on great adventures by entering the Cave of Trials.
-
Bazaar Experience - This achievement quest rewards players with a special Festival Souvenir Hebona Robe sewing pattern with the opportunity to win a Festival Commemorative Luxury Equipment Bag Box, 20,000 EXP, and 25 instant prize tickets after completing all objectives.
- 14th Anniversary Hotdays - Players will be able to receive a special 14th Anniversary On-Time Gift Box every week and receive 10 Night Bazaar Stickers every weekend on Saturday and Sunday by logging in during the event.
- Festia Instant Prize Event - Try your luck at the Capsule Machine, located next to Fez in Festia, to open the Instant Prize window with 20,000 gold or one Instant Prize Ticket, which can be gained by participating in certain 14th Anniversary events.
On the heels of the 14th anniversary celebratory activities, players should expect Mabinogi servers to fully integrate on April 14. A new server, Erinn, will be launched on this date. It’s an exciting time to join the world of Mabinogi!
For more information on Mabinogi’s 14th anniversary and server merge, visit the official website and follow @mabinogi on Facebook for the latest updates.
Assets: Anniversary image | Server Merge image
Social Media: Facebook / Twitter / Instagram / Twitch / YouTube / Discord
About Mabinogi http://mabinogi.nexon.net/
Released in 2008, Mabinogi is an immersive free-to-play MMORPG world where mystical adventures await. Create anime-inspired heroes with thousands of customization options, such as hairstyles, facial features and outfits. Select from dozens of talents ranging from professional gunslingers and archers to musicians, tailors and cooks. Players can enjoy the game on their own terms, taking the perilous path of an adventurer or build a thriving business using unique trade skills.
About Nexon America Inc. https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005803/en/
Contact information
Brian Klotz
Nexon America
pr@nexon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom